Evidence map›Paper›PMID 34742157›Full record

Observational studyEuropean journal of cancer (Oxford, England : 1990)2021

Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment.

Tania Buttiron Webber, Nicoletta Provinciali, Marco Musso, Martina Ugolini, Monica Boitano, Matteo Clavarezza, Mauro D'Amico, Carlotta Defferrari, Alberto Gozza, Irene Maria Briata and 12 more

Registry-linked trialOpen access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of cancer (Oxford, England : 1990), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04932863 (A Prospective Observational Non Interventional Study of Reactogenicity and Safety of the BNT162b2 Messenger Ribonucleic Acid), which is not on this map. Cited by 31 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 5 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04932863 completednot on this map

A Prospective Observational Non Interventional Study of Reactogenicity and Safety of the BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment

TypeobservationalSponsorEnte Ospedaliero Ospedali GallieraRan2021 to 2023Enrolled300ConditionsNeoplasms, Cancer, Treatment-RelatedArmsBNT162b2 mRNA Covid-19 Vaccine
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 5 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Observational
  8. Review
  9. Review
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 2 countries.

Tania Buttiron WebberE.O. Ospedali Galliera, Genoa, 16128, Italy.
Nicoletta ProvincialiE.O. Ospedali Galliera, Genoa, 16128, Italy.
Marco MussoE.O. Ospedali Galliera, Genoa, 16128, Italy.
Martina UgoliniE.O. Ospedali Galliera, Genoa, 16128, Italy.
Monica BoitanoE.O. Ospedali Galliera, Genoa, 16128, Italy.
Matteo ClavarezzaE.O. Ospedali Galliera, Genoa, 16128, Italy.
Mauro D'AmicoE.O. Ospedali Galliera, Genoa, 16128, Italy.
Carlotta DefferrariE.O. Ospedali Galliera, Genoa, 16128, Italy.
Alberto GozzaE.O. Ospedali Galliera, Genoa, 16128, Italy.
Irene Maria BriataE.O. Ospedali Galliera, Genoa, 16128, Italy.
Monica MagnaniE.O. Ospedali Galliera, Genoa, 16128, Italy.
Fortuna PaciollaE.O. Ospedali Galliera, Genoa, 16128, Italy.
Nadia MenghiniE.O. Ospedali Galliera, Genoa, 16128, Italy.
Emanuela MarcenaroDepartment of Experimental Medicine (DIMES), University of Genoa and IRCCS IST-Ospedale San Martino, Genoa, Italy.
Raffaele De PalmaDepartment of Internal Medicine (DIMI), University of Genoa, Genoa, Italy; IRCCS IST-Ospedale Policlinico San Martino, Genoa, 16132, Italy.
Nicoletta SacchiE.O. Ospedali Galliera, Genoa, 16128, Italy.
Leonello InnocentiE.O. Ospedali Galliera, Genoa, 16128, Italy.
Giacomo SiriE.O. Ospedali Galliera, Genoa, 16128, Italy.
Oriana D'EcclesiisEuropean Institute of Oncology IRCCS, Milan, 20141, Italy.
Isabella CevascoE.O. Ospedali Galliera, Genoa, 16128, Italy.
Sara GandiniEuropean Institute of Oncology IRCCS, Milan, 20141, Italy.
Andrea DeCensiE.O. Ospedali Galliera, Genoa, 16128, Italy; European Institute of Oncology IRCCS, Milan, 20141, Italy; Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. Electronic address: andrea.decensi@galliera.it.
Ente Ospedaliero Ospedali Galliera · ITEuropean Institute of Oncology · ITOspedale Policlinico San Martino · ITQueen Mary University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeInitial findings in patients with cancer suggest a lower seroconversion to SARS-CoV-2 vaccination possibly related to myelo-immunosuppressive therapies. We conducted a prospective study to assess factors predicting poor seroconversion and adverse events following immunisation (AEFI) to the BNT162b2 vaccine in patients on active treatment. PATIENTS AND

methodsCancer patients, candidates to two doses of BNT162b2 SARS-CoV-2 vaccination, were enrolled. Patients on active surveillance served as controls. The primary endpoint was poor seroconversion (anti S1/S2 IgG < 25 AU/mL) after 21 days from the second dose.

resultsBetween March and July 2021, 320 subjects were recruited, and 291 were assessable. The lack of seroconversion at 21 days from the second dose was 1.6% (95% CI, 0.4-8.7) on active surveillance, 13.9% (8.2-21.6) on chemotherapy, 11.4% (5.1-21.3) on hormone therapy, 21.7% (7.5-43.7) on targeted therapy and 4.8% (0.12-23.8) on immune-checkpoint-inhibitors (ICI). Compared to controls, the risk of no IgG response was greater for chemotherapy (p = 0.033), targeted therapy (0.005) and hormonotherapy (p = 0.051). Lymphocyte count < 1 × 10

conclusionChemotherapy, targeted therapy, hormone therapy, lymphocyte count < 1 × 10 GOV IDENTIFIER: NCT04932863.

Indexed as

Immunogenicity, VaccineVaccinationVaccine EfficacyAgedAntibodies, ViralBiomarkersBNT162 VaccineCase-Control StudiesCOVID-19FemaleHumansMaleMiddle AgedNeoplasmsProspective StudiesRisk FactorsAntibodies, ViralBiomarkersBNT162 VaccineAntibody responses to the BNT162b2 vaccineCancer biological treatmentCancer chemotherapyCancer hormone therapyCancer immunotherapyCancer target therapyCOVID-19 vaccine in cancer patientsImmunogenicitySARS-CoV-2 vaccineSARS-CoV-2 vaccine adverse effects

Identifiers

PMID34742157
PMCPMC8502731
OpenAlexW3207788380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.